Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development.
Researched for
Weight reduction in overweight and obesity (GLORY programme)Glycaemic control in type 2 diabetes (DREAMS programme)Reduction of liver fat and cardiometabolic risk factors
Official status
US: Research only
No FDA approval. Eli Lilly holds the rights outside China; the substance is in clinical investigation in the US (investigational).
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
4 observations · 2 tiers
Human RCT
2
Human trial
2
03
What the studies show
Human RCT
Mensch
Ji L. et al. 2025
Clinically relevant weight reduction in adults with overweight or obesity over 48 weeks documented in a phase-3 trial
What does NOT follow: Study population limited to Chinese adults; long-term data beyond the trial duration are pending. Not a usage or quantity recommendation.
Human RCT
Mensch
Zhang B. et al. 2024
Improvement of glycaemic parameters in adults with type 2 diabetes reported in a phase-2 trial
What does NOT follow: Phase-2 data; the diabetes indication is still under regulatory review in China. Transferability to other populations not established.
Human trial
Mensch
Ji L. et al. 2023
Reduction of liver fat content observed in a phase-2 dose-ranging obesity trial
What does NOT follow: Secondary endpoint of a phase-2 trial; confirmatory studies with liver-specific clinical endpoints are pending.
Human trial
Mensch
Ji L. et al. 2022
Gastrointestinal events (including decreased appetite, nausea, diarrhoea, vomiting) were the most commonly reported adverse events in a dose-dependent manner
What does NOT follow: Profile similar to other incretin-based substances; in the phase-1b trial events were predominantly mild to moderate.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 132 h. Pure pharmacokinetic model — not a dosing recommendation.
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
11
Legal status by country
Country
Status
Note
Checked
United States
Research only
No FDA approval. Eli Lilly holds the rights outside China; the substance is in clinical investigation in the US (investigational).
2026-06-07
Germany
Research only
No EMA approval. Not authorised as a medicinal product in Germany; relevant at most within clinical trials (investigational).
2026-06-07
CN
Prescription
China's NMPA approved mazdutide on 27 June 2025 for chronic weight management in adults with overweight or obesity (first approved dual GCG/GLP-1 receptor agonist). A further filing for type 2 diabetes is under review.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial